Top

Published in:

01-03-2020 | Prostate Cancer | Original Article

Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy

Authors: Tomasz Barelkowski, MD, Peter Wust, MD, David Kaul, MD, Sebastian Zschaeck, MD, Waldemar Wlodarczyk, PhD, Volker Budach, MD, Pirus Ghadjar, MD, Marcus Beck, MD

Published in: Strahlentherapie und Onkologie | Issue 3/2020

Abstract

Purpose

To evaluate treatment outcomes for patients with localized prostate cancer who were treated with dose-escalated primary image-guided radiation therapy (IGRT).

Methods

We retrospectively analyzed 88 consecutive patients treated using helical tomotherapy with daily megavoltage CTs (MVCT). Patients were prescribed daily doses of 1.8 Gy to the planning target volume (PTV) and 2 Gy to the clinical target volume (CTV). Low- and favorable intermediate-risk patients received a minimum total dose of 72 Gy to the PTV and up to 80 Gy to the CTV. Unfavorable intermediate-risk and high-risk patients received a minimum total dose of 75.6 Gy to the PTV and up to 84 Gy to the CTV. We assessed freedom from biochemical relapse (FFBF), 5‑year biochemical recurrence-free survival (5-bRFS), distant metastasis-free survival (5-dMFS), and cancer-specific survival (5-CSS) as well as acute and late genitourinary (GU) and gastrointestinal (GI) toxicity.

Results

Among our cohort, 11.4% were low-risk, 50% intermediate-risk, and 38.6% high-risk patients according to the D’Amico criteria. Median follow-up was 66 months (range 8–83 months). FFBF was 100%, 97.7%, and 90.7%; 5‑bRFS was 100%, 92.8%, and 70.4%; 5‑dMFS was 100%, 92.7%, and 70.4%; and 5‑CSS was 100%, 97.4%, and 89.8% for low-, intermediate-, and high-risk patients, respectively. Grades 2 and 3 toxicity occurred at the following rates: acute GU toxicity 39.8% and 1.1%, acute GI toxicity 12.5% and 0%, late GU toxicity 19.3% and 4.5%, and late GI toxicity 4.5% and 1.1% of patients, respectively. No toxicity >grade 3 was observed.

Conclusion

Risk-adapted dose-escalated IGRT with helical tomotherapy of up to 84 Gy is a feasible and well-tolerable treatment scheme with promising oncological results.

Available only for authorised users

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE, Protec TSG (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220 CrossRefPubMed

Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79(5):1310–1317. https://doi.org/10.1016/j.ijrobp.2010.01.006 CrossRefPubMed

Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988. https://doi.org/10.1016/j.ijrobp.2008.02.073 CrossRefPubMed

Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5‑year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063. https://doi.org/10.1016/j.ijrobp.2010.03.049 CrossRefPubMed

Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ (2016) Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3‑dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Cancer 122(13):2004–2011. https://doi.org/10.1002/cncr.29983 CrossRefPubMed

Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H (2008) Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71(2):330–337. https://doi.org/10.1016/j.ijrobp.2007.10.004 CrossRefPubMed

Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85(3):686–692. https://doi.org/10.1016/j.ijrobp.2012.05.023 CrossRefPubMed

Ghadjar P, Jackson A, Spratt DE, Oh JH, Munck af Rosenschold P, Kollmeier M, Yorke E, Hunt M, Deasy JO, Zelefsky MJ (2013) Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Eur Urol 64(6):931–938. https://doi.org/10.1016/j.eururo.2013.02.001 CrossRefPubMedPubMedCentral

Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J, Kovarik J (2015) Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Strahlenther Onkol 191(4):338–346. https://doi.org/10.1007/s00066-014-0806-y CrossRefPubMed

10.

Petrongari MG, Landoni V, Saracino B, Gomellini S, Arcangeli S, Iaccarino G, Pinnaro P, Arcangeli G, Strigari L (2013) Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control. J Exp Clin Cancer Res 32:103. https://doi.org/10.1186/1756-9966-32-103 CrossRefPubMedPubMedCentral

11.

Eade TN, Guo L, Forde E, Vaux K, Vass J, Hunt P, Kneebone A (2012) Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy. BJU Int 109(11):1655–1660. https://doi.org/10.1111/j.1464-410X.2011.10668.x CrossRefPubMed

12.

Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G (2008) Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 72(3):799–807. https://doi.org/10.1016/j.ijrobp.2008.01.040 CrossRefPubMed

13.

Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H (2018) Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol 4(6):e180039. https://doi.org/10.1001/jamaoncol.2018.0039 CrossRefPubMedPubMedCentral

14.

Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M, Hunt M (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84(1):125–129. https://doi.org/10.1016/j.ijrobp.2011.11.047 CrossRefPubMed

15.

Wust P, Joswig M, Graf R, Bohmer D, Beck M, Barelkowski T, Budach V, Ghadjar P (2017) Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy: comparison of gold marker-based registrations with native MVCT. Strahlenther Onkol. https://doi.org/10.1007/s00066-017-1141-x CrossRefPubMed

16.

D’Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP (2001) Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166(6):2185–2188CrossRef

17.

Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z (2017) Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer. BJU Int. https://doi.org/10.1111/bju.13903 CrossRefPubMed

18.

Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69(6):1095–1101. https://doi.org/10.1016/j.urology.2007.03.042 CrossRefPubMedPubMedCentral

19.

Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029 CrossRef

20.

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA, Macias V, Olive PA, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villa S, de la Haza PA, Calvo FA (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16(3):320–327. https://doi.org/10.1016/S1470-2045(15)70045-8 CrossRefPubMed

21.

Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L (2016) Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol 34(15):1748–1756. https://doi.org/10.1200/JCO.2015.64.8055 CrossRefPubMed

22.

Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825–836. https://doi.org/10.1016/j.eururo.2014.07.010 CrossRefPubMed

23.

Byrne K, Hruby G, Kneebone A, Whalley D, Guo L, McCloud P, Eade T (2017) Late genitourinary toxicity outcomes in 300 prostate cancer patients treated with dose-escalated image-guided intensity-modulated radiotherapy. Clin Oncol. https://doi.org/10.1016/j.clon.2017.03.006 CrossRef

24.

Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosenschold P, Oh JH, Hunt M, Kollmeier M, Happersett L, Yorke E, Deasy JO, Jackson A (2014) Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 88(2):339–344. https://doi.org/10.1016/j.ijrobp.2013.10.042 CrossRefPubMedPubMedCentral

Title: Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy
Authors: Tomasz Barelkowski, MD
Peter Wust, MD
David Kaul, MD
Sebastian Zschaeck, MD
Waldemar Wlodarczyk, PhD
Volker Budach, MD
Pirus Ghadjar, MD
Marcus Beck, MD
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: Strahlentherapie und Onkologie / Issue 3/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-019-01562-2

At a glance: The STEP trials

Springer Medicine

Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Erste erfolgversprechende Ergebnisse der Kombination aus Strahlentherapie und Pembrolizumab beim metastasierten nichtkleinzelligen Lungenkarzinom

36. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik

Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results

Re-irradiation for humeral epicondylitis

Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years)

Erhaltene sexuelle Funktion nach hochdosierter bildgestützter Protonentherapie des Prostatakarzinoms